Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

X
Trial Profile

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms DEVOTE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Jun 2021 Results (n=369) assessing association between cardiovascular autonomic neuropathy and risk of heart failure in patients with Type 2 Diabetes presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 16 Jun 2020 Data from this trial used to assess derived time-in-range is associated with MACE in T2D presented at the 80th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top